Get the Stockscreener App
4.045
6.03%
0.145
Polypid Ltd stock is traded at $4.045, with a volume of 31,999.
It is up +6.03% in the last 24 hours and down -12.95% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$3.90
Open:
$3.95
24h Volume:
31,999
Relative Volume:
0.17
Market Cap:
$78.42M
Revenue:
-
Net Income/Loss:
$-33.63M
P/E Ratio:
-2.1151
EPS:
-1.9124
Net Cash Flow:
$-47.63M
1W Performance:
-19.71%
1M Performance:
-12.95%
6M Performance:
-13.85%
1Y Performance:
+12.36%
1-Day Range:
$3.90
$4.11
1-Week Range:
$3.65
$4.84
52-Week Range:
$3.06
$5.73
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.09 | 74.78M | 0 | -33.63M | -47.63M | -1.9124 |
VRTX
Vertex Pharmaceuticals Inc
|
485.40 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
674.35 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
907.15 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.37 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.43 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
PolyPid Ltd (PYPD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PolyPid Ltd (PYPD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
PYPD|PolyPid Ltd|Price:3.900|Chg%:-0.340 - TradingKey
Antibacterial Drug Partnership Accelerates PolyPid Commercial Path - Streetwise Reports
PolyPid, Azurity Sign US$330M Deal for D-PLEX100 - Streetwise Reports
H.C. Wainwright Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
H.C. Wainwright reiterates Buy on PolyPid stock, $13 target - Investing.com UK
PolyPid price target lowered to $12 from $13 at Craig-Hallum - TipRanks
H.C. Wainwright reiterates Buy on PolyPid stock, $13 target By Investing.com - Investing.com Nigeria
PYPD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $13 - GuruFocus
Azurity Pharmaceuticals Announces Plans To Commercialize D-PLEX100 In The United States And Canada Through Exclusive Partnership With PolyPid - marketscreener.com
Roth Capital reaffirms Buy on PolyPid after exc... - Pluang
PolyPid, Azurity sign surgical site infection drug deal - Reuters
PolyPid, Azurity Pharmaceuticals Agree to Exclusive Commercial Partnership in US and Canada - Contract Pharma
Roth says Azurity deal validates D-PLEX100, sees limited near-term revenue - TipRanks
PolyPid Ltd. (PYPD) Faces Sharp Decline: Navigating Key Support LevelsQuality ETF - dars.gov.et
PolyPid Locks in a Transformative Deal Worth Over $320 Million, With Additional Major Royalty Potential - TipRanks
Azurity Announces Plans to Commercialize D-PLEX100 in the - GlobeNewswire
Israeli PolyPid signs $320 million deal to sell drug preventing surgical infections in US, Canada - The Jerusalem Post
PolyPid signs $320M deal with Azurity for D-PLEX100 in U.S., Canada - Investing.com South Africa
PolyPid Strikes Azurity Commercialization Deal for D-PLEX100 in U.S. and Canada - TipRanks
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada - The Manila Times
PolyPidEligible for up to $300 Mln in Addi - Moomoo
PolyPid's D-PLEX100 Shows 60% Lower Surgical Infection Risk in Phase 3 - Stock Titan
Polypid Locks In A Transformative Deal Worth Over $320 Million, With Additional Major Royalty Potential - Menafn
PolyPid (PYPD) awards director 9,132 stock options vesting through 2030 - Stock Titan
PolyPid (NASDAQ: PYPD) grants 46,000 stock options to U.S. COO - Stock Titan
PolyPid (PYPD) awards CFO 49,000 stock options at $4.46 - Stock Titan
PolyPid Ltd. (PYPD) grants director 9,132 stock options at 4.46 - Stock Titan
PolyPid (PYPD) awards director 9,132 stock options at $4.46 - Stock Titan
PolyPid (PYPD) grants director Dror-Darwish Nir 9,132 stock options at $4.46 - Stock Titan
PolyPid (PYPD) director awarded 9,132 stock options at $4.46 strike price - Stock Titan
PolyPid (PYPD) CEO receives grant of 149,000 stock options - Stock Titan
PolyPid | 4: Statement of changes in beneficial ownership of securities-Officer Missulawin Jonathan - Moomoo
PolyPid Ltd. (PYPD) boosts option pool by 1.5M shares and clears CEO grant - Stock Titan
PolyPid (PYPD) Climbs 6% as Biotech Stock Tests Key ResistanceAndrews Pitchfork - dars.gov.et
PolyPid (PYPD) Climbs 3.97% as Shares Test Key Resistance ZoneAI Trade Signals - dars.gov.et
PolyPid (PYPD) The Citizens Life Sciences Conference 2026 Summary - Quartr
PolyPid (PYPD) Lytham Partners Spring 2026 Investor Conference Summary - Quartr
PolyPid Ltd stock and its pipeline. A closer look at the drug-delivery specialist - ad-hoc-news.de
PYPDPolypid Ltd Latest SEC Filings - Finviz
Price to sales forward of PolyPid Ltd. – NASDAQ:PYPD - TradingView
Price to earnings forward of PolyPid Ltd. – NASDAQ:PYPD - TradingView
Enterprise value to revenue forward of PolyPid Ltd. – NASDAQ:PYPD - TradingView
Price to book forward of PolyPid Ltd. – NASDAQ:PYPD - TradingView
PolyPid Ltd. (PYPD) Surges 4.6%, Approaches Key Resistance at $5.22Exhaustion Gap - dars.gov.et
PYPD Forecast — Price Target — Prediction for 2027 - TradingView
PolyPid Ltd. Actuals & Estimates (NASDAQ:PYPD) - TradingView
PolyPid Ltd. Actuals & Estimates (FWB:2PV) - TradingView
2PV Forecast — Price Target — Prediction for 2027 - TradingView
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):